Company Page
Brano Therapeutics
Founders
Brano Therapeutics is a Singapore-based biotechnology spin-off from Duke-NUS Medical School developing novel small-molecule therapies targeting metabolic dysfunction in Heart Failure with preserved Ejection Fraction (HFpEF). The company's pipeline is grounded in preclinical research demonstrating that restoring a disrupted nutrient processing pathway can significantly reduce cardiac stiffness and improve heart function. Backed by TIBS, SEEDS, SGInnovate, and Duke-NUS' LIVE Ventures, Brano aims to advance its lead compounds into clinical trials by 2029.
Company Founded in

